<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, April 17, 2020 (HealthDay News) — In rapid guidelines issued by the Infectious Diseases Society of America (IDSA), recommendations are presented for the treatment and management of coronavirus disease 2019 (COVID-19).<\/p>\n
Adarsh Bhimraj, M.D., from the Cleveland Clinic, and colleagues developed evidence-based rapid guidelines to support patients, clinicians, and other health care professionals in the treatment and management of COVID-19. A multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise was formed by the IDSA.<\/p>\n
The guideline panel agreed on seven treatment recommendations. The recommendations include hydroxychloroquine\/chloroquine in the context of a clinical trial for patients who have been admitted to the hospital with COVID-19; hydroxychloroquine\/chloroquine plus azithromycin is recommended only in the context of a clinical trial. The combination of lopinavir\/ritonavir is recommended only in the context of a clinical trial for patients admitted to the hospital with COVID-19. The panel suggests against use of corticosteroids for patients admitted with COVID-19 pneumonia; for those admitted with acute respiratory distress syndrome due to COVID-19, corticosteroids are recommended in the context of a clinical trial. Tocilizumab is recommended only in the context of a clinical trial, and convalescent plasma is recommended in the context of a clinical trial among those admitted with COVID-19.<\/p>\n
“The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19,” the authors write in the abstract for the guideline.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n